Pancreas tumor, Chronic pancreatitis, Autoimmune pancreatitis, Gallblader polyp, Biliary tract tumor
Conditions
Interventions
Contrast enhanced endoscopic ultrasonography using perflubutane
MRI
enhanced CT
endoscopic ultrasonography without perflubutane
Sponsors
Department of Endoscopy The Jikei University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who are suspected pacreatobiliary disease by ohter modality(CT, US, MRI). 2.Performance status; 0,1,2. 3.Patients who got ingormed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with allergy to egg. 2.Patients with arteriovenous shunt in cardia. 3.Patients woth severe cardiac disease. 4.Patients with sebere lung disorder. 5.Female patients with pregnacy or nursing. 6.Patients with mental aliments who cannot sign up for this clinical trial. 7.Patients with adverse events to perflubutane including minimal side effects. 8.Inadequate patients to participate in this study, in the judgement of an attending doctor or inspection physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate whether contrast enhanced endoscopic ultrasonography can provide a reliable diagnosis for pancreatobbiliary disease, we compare the diagnostic accuracy of contrast enhanced endoscopic ultrasonography with enhanced conputed tomography, magnetic resonance imaging, and endoscopic ultrasonography without perflubutane | — |
Countries
Japan
Contacts
Public ContactMasafumi Chiba
The Jikei University School of Medicine Department of Endoscopy
Outcome results
None listed